Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2016)
15 slides from Resonance Health's shareholder meeting presentation, Nov 24, 2016
Slide 1: Annual General Meeting
ASX: RHT For personal use only Resonance Health Limited ASX: RHT Annual General Meeting 24th November 2016
Slide 2: Disclaimer
Disclaimer ___________________________________________________________________________________________ For personal use only This presentation contains forward looking statements which may be subject to significant uncertainties outside of the Company’s control. No representation is made as to the a
Slide 3: Resonance Health Limited
Resonance Health Limited ___________________________________________________________________________________________ • RHT develops and delivers non-invasive For personal use only quantitative medical imaging software and services • Market capitalisation ~ AU$10M (approx. 400 million shares on issue
Slide 4: Year in Review: Growth and Development
Year in Review: Growth and Development ___________________________________________________________________________________________ FerriScan For personal use only Grow established markets • Record clinical image analyses • 25 new sites Develop new markets • Sickle Cell: 25% sales increase USA • Canc
Slide 5: Year in Review: HepaFat-Scan Studies
Year in Review: HepaFat-Scan Studies ___________________________________________________________________________________________ For personal use only 2015 2016 2017 2018 2019 Paediatric NAFLD USA Unexplained UK UK Hyperferritinaemia UK UK Diabetes (x2) Malaysia Malaysia AUS AUS Surgery (x2) USA Pop
Slide 6: Strategy
Strategy _______________________________________________________________________________________________ For personal use only 1 2 3 4 FerriScan New Reimbursement Diversify & HepaFat- Advances Scan - Grow - Evaluate - Efficiencies - Broaden established potential new and further product and new CPT c
Slide 7: The Liver and Beyond
The Liver and Beyond _______________________________________________________________________________________________ For personal use only • Expertise in the liver other organ systems - Heart, Bone Marrow, Spleen and Pancreas • HepaFat-Scan + Pancreatic fat - Fatty Liver, Diabetes, Metabolic Syndrom
Slide 8: FerriScan: Strategy
FerriScan: Strategy _______________________________________________________________________________________________ Develop new markets For personal use only 1) Sickle Cell Disease (USA – 100k patients) – 15% patients receive regular blood transfusions – Evidence shows benefit of FerriScan – Guideli
Slide 9: HepaFat-Scan: Strategy
HepaFat-Scan: Strategy ___________________________________________________________________________________________ • KOLs using in 8 active studies For personal use only – Generate evidence to enhance uptake – 2 studies near completion • Pharma trials Combination with FerriScan • Cancer Survivors –
Slide 10: Reimbursement: Strategy
Reimbursement: Strategy _______________________________________________________________________________________________ • FerriScan currently reimbursed in: For personal use only – UK (NHS trusts) – Canada (MOH Ontario) – US (selected payers) – Germany (case-by-case) 1) USA - Obtain advice around re
Slide 11: New Advances: Strategy
New Advances: Strategy _______________________________________________________________________________________________ For personal use only • Advances in Computer Science (Machine Learning) – Develop new low cost LIC measurement product – Opens large volume markets, e.g. developing countries – Appl
Slide 12: Diversify: Strategy
Diversify: Strategy _______________________________________________________________________________________________ New investigational products For personal use only • Bone marrow iron assessment – 50k+ transplants pa regulatory filing • Pancreatic fat assessment (Diabetes) • Organ volume measureme
Slide 13: Product Status Summary
Product Status Summary _______________________________________________________________________________________________ For personal use only Research Proof of Validation Regulatory On Market Reim- Concept Clearance bursement FerriScan UK / Can Cardiac T2* Can HepaFat-Scan Bone Marrow Iron Pancreatic
Slide 14: Summary: 2017 Focus
Summary: 2017 Focus _______________________________________________________________________________________________ • Investing in growth and diversification For personal use only • New markets for established products – Sickle cell disease – Cancer survivors – Unexplained hyperferritinaemia • Ferri
Slide 15: www.resonancehealth.com
ASX: RHT For personal use only www.resonancehealth.com
Resonance Health — Shareholder Meeting (November 2016) on 6ix